Evofem and Aditxt amend merger agreement again; extend equity investment and closing deadlines

Evofem Biosciences, Inc.

Third Parent Equity Investment date moved from Sept 6 to Sept 30, 2024; Fourth from Sept 30 to Oct 31, 2024.
Outside consummation date (Section 8.1(b)(ii)) extended to November 29, 2024.
Aditxt must purchase $1.5M of Series F-1 preferred stock on each of the new Third and Fourth investment dates.
No other changes to merger terms; previous conditions and consideration unaffected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.